Latest News

  • Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA Read More
  • Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic Read More
  • Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Read More

Investors

Learn More

Working at Alkermes

Join Our Team